Enanta Pharmaceuticals (ENTA) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and strategic focus

• Longstanding expertise in virology, with a history of developing protease inhibitors for hepatitis C and expanding into hepatitis B and respiratory viruses.

• Current focus includes RSV, COVID-19, and a new immunology pillar targeting mast cell-associated diseases.

• Immunology portfolio initiated with a KIT inhibitor program for chronic spontaneous urticaria (CSU), aiming to expand further.

RSV program updates and market landscape

• Two phase II RSV compounds: zelicapavir (N protein inhibitor) in pediatric and high-risk adult studies, and EDP-323 (L protein inhibitor) in a challenge study.

• Upcoming data readouts: EDP-323 in Q3 and zelicapavir pediatric study in Q4, enabling portfolio decisions.

• Antiviral treatments seen as essential despite RSV prophylaxis advances, due to limited vaccine uptake and potential resistance.

• Replication inhibitors (zelicapavir, EDP-323) target infected cells, potentially offering advantages over fusion inhibitors.

Clinical trial design and future plans

• Pediatric zelicapavir study focuses on safety, PK, and virology endpoints, with phase III planning underway if data are supportive.

• High-risk adult RSV study aims for clinically meaningful symptom reduction, with full enrollment targeted for the upcoming Northern Hemisphere season.

• Positive pediatric data would accelerate phase III initiation without waiting for adult results.